Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
-
In conclusion two novel series of furo pyrimidin amines and
2024-07-19
In conclusion, two novel series of furo[2,3-]pyrimidin4-amines and 7-pyrrolo[2,3-]pyrimidin-4-amines which exhibit potent in vitro inhibitor activity against ACK1 have been identified and evaluated. 1,3-Dithiolane-substituted pyrrolopyrimidine displays excellent ACK1 cellular inhibition, good kinase
-
br Acknowledgments We thank the anonymous
2024-07-19
Acknowledgments We thank the anonymous reviewers for their constructive comments on the manuscript, and also thank Dr. Hans-U. Dahms for his comments on the manuscript. This work was supported by a grant from the National Research Foundation (2009-0071218) funded to Young-Mi Lee. This work was al
-
The gene SRD A encodes the reductase enzyme
2024-07-19
The gene SRD5A2 encodes the 5-α-reductase enzyme, which converts testosterone into dihydrotestosterone. Although dihydrotestosterone levels are considerably lower than testosterone, dihydrotestosterone has a five-fold stronger binding capacity to the androgen receptor and, thereby, a considerably mo
-
The first natural product described
2024-07-19
The first natural product described as 5-LO inhibitor was the polyphenol nordihydroguaiaretic Betaine receptor from the Mexican dessert plant Larrea divaricata in 1981 (Bokoch and Reed, 1981), short after the initial identification of 5-LO in 1979 (Borgeat and Samuelsson, 1979). Long time before mP
-
br Methods br Results br Discussion br Acknowledgements
2024-07-19
Methods Results Discussion Acknowledgements This work was supported by the National Institutes of Health [Grant R21 NS081429], a Pilot Grant from the Vanderbilt Conte Center supported by the National Institutes of Health [Grant P50 M096972], and by the Department of Anesthesiology at V
-
It has been known that LOX
2024-07-19
It has been known that 5-LOX is the rate-limiting enzyme for the products of LTs, and LTs actively participate in the activation of neutrophils [10]. In our study, we determined whether 5-LOX was upregulated in pancreatic tissues during ANP. Moreover, we investigated whether the inhibition of expres
-
In order to improve the
2024-07-19
In order to improve the methodology of the synthesis of steroidal derivatives, our goal was the investigation of aza-Michael addition of different N-nucleophiles to 16-dehydropregnenolone in the presence of [DBU][OAc] as catalyst and reaction medium. Michael addition of electron deficient steroidal
-
br Conflicts of interest br Acknowledgments The authors
2024-07-19
Conflicts of interest Acknowledgments The authors acknowledge National Institute for Medical Research Development (NIMAD) project no. 940943 and National Research Institute for Science Policy (NRISP) no. 1456 for financial support of this work. AM appreciates National Institute for Genetic Eng
-
Fencilli et al reported derivatives of PHA
2024-07-19
Fencilli et al. reported derivatives of PHA-680626 (15) which demonstrated strong anti-proliferative activity against large group of leukaemia cell lines including IM-resistant BAF3 cells expressing mutants like T315I, M351T and E255K. Decrease in Histone H3 phosphorylation led to induction of endo-
-
In conclusion we report that the widely prescribed drug VPA
2024-07-19
In conclusion, we report that the widely prescribed drug VPA exerts therapeutic effects on optic nerve demyelination and retinal degeneration in a mouse model of MS. Our findings raise an interesting possibility that combination therapy of VPA and ASK1 inhibition may be useful for treatment of autoi
-
Limitations of this study include the use of
2024-07-18
Limitations of this study include the use of HL-1 cardiomyocytes, which show different characteristics than primary cardiomyocytes [56]. Furthermore, sustained TAC in Ampkα1-deficient mice did not favorably influence cardiac function [33]. It must be kept in mind that global Ampkα1-deficiency may af
-
Luo Dehm Raj Luo Attard Balk Bevan
2024-07-18
Luo, Dehm, Raj. Luo, Attard, Balk, Bevan, Burnstein, Cato, Cherkasov, De Bono, Dong, Gao, Gleave, Heemers, Kanayama, Kittler, Lang, Lee, Logothetis, Matusik, Plymate, Sawyers, Selth, Soule, Tilley, Weigel, Zoubeidi, Dehm, Raj. Luo, Attard, Balk, Bevan, Burnstein, Cato, Cherkasov, De Bono, Dong,
-
A 77636 hydrochloride australia Kuda et al reported that the
2024-07-18
Kuda et al. (1997) reported that the activity of aminopeptidase A (ApA) but not aminopeptidase B (ApB) nor aminopeptidase N (ApN) was decreased in plasma from patients with Alzheimer's disease (AD). More recently Puertas et al. (2013) reported that the activities of plasma ApA, ApB, ApN and IRAP wer
-
Ginsenosides are the major bioactive
2024-07-18
Ginsenosides are the major bioactive constituents of the Panax ginseng root, which contain many types of ginsenosides including Rb1, Rg1, Rc, and Rg3. The ginsenoside Rb1 appears to be the most abundant of the bioactive ginsenosides [15]. Rb1 exhibits antiinflammatory, anticarcinogenic, and antioxid
-
There are two ways to transport FFAs into cells
2024-07-18
There are two ways to transport FFAs into cells. First by passive diffusion. Second as the putative long-chain fatty N-Nonyldeoxynojirimycin transporters are proposed, CD36 the plasma membrane-associated fatty acid-binding protein (FABPpm) and fatty acid transport proteins (FATP) [11], where CD36 i